Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,011.12 -11.09 (-0.22%) Dow
37,775.38 +22.07 (+0.06%) Nasdaq
15,601.50 -81.87 (-0.52%) Bitcoin USD
63,541.46 +1,861.93 (+3.02%) CMC Crypto 200
1,313.74 +428.20 (+48.35%)
JNJ Jan 2025 210.000 call
| Previous close | 0.2300 |
| Open | 0.1800 |
| Bid | 0.0800 |
| Ask | 1.4000 |
| Strike | 210.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.1800 - 0.2300 |
| Contract range | N/A |
| Volume | |
| Open interest | 477 |
- Reuters
US FDA mandates label updates on CAR-T cancer therapies
The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of T-cell blood cancer in patients who use these therapies. The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medication guide. In January, the FDA asked a host of drugmakers including Gilead Sciences, Johnson & Johnson and Novartis to add a boxed warning to their CAR-T cancer therapies, as it received reports of patients developing a type of T-cell blood cancer after being treated with them.
ReutersJ&J wins trial over Florida woman who claimed its baby powder caused her cancer
A Florida jury on Thursday concluded that Johnson & Johnson's baby powder talc product did not cause the ovarian cancer of a Florida woman who died in 2019. The lawsuit was brought by family members of Patricia Matthey, a Sarasota County resident who used Johnson's baby powder daily from 1965 until August 2016, when she was diagnosed with ovarian cancer, according to her family's lawsuit. J&J's Worldwide Vice President of Litigation Erik Haas said the company was vindicated by the jury's decision.
ZacksTop Stock Reports for NVIDIA, Alphabet & Johnson & Johnson
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ).
